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OBJECTIVE: Upper airway resistance syndrome is a sleep-disordered breathing syndrome that is characterized by
repetitive arousals resulting in sympathetic overactivity. We aimed to determine whether upper airway
resistance syndrome was associated with poorly controlled hypertension.
METHODS: A total of 40 patients with resistant hypertension were enrolled in the study. All of the patients
underwent polysomnographic examinations and 24-hour ambulatory blood pressure monitoring to exclude
white coat syndrome and to monitor treatment efficiency. Among 14 upper airway resistance syndrome
patients, 2 patients had surgically correctable upper airway pathologies, while 12 patients were given positive
airway pressure therapy.
RESULTS: All patients underwent polysomnographic examinations; 22 patients (55%) were diagnosed with
obstructive sleep apnea and 14 patients (35%) were diagnosed with upper airway resistance syndrome,
according to American Sleep Disorders Association criteria. The patients with upper airway resistance syndrome
were younger and had a lower body mass index compared with other patients, while there were no difference
between the blood pressure levels and the number of antihypertensive drugs. The arousal index was positively
correlated with systolic blood pressure level (p=0.034; rs = 0.746), while the Epworth score and AHI were
independent of disease severity (p=0.435, rs = 0.323 and p=0.819, rs = -0.097, respectively). Eight patients were
treated with positive airway pressure treatment and blood pressure control was achieved in all of them,
whereas no pressure reduction was observed in four untreated patients.
CONCLUSIONS: We conclude that upper airway resistance syndrome is a possible secondary cause of resistant
hypertension and that its proper treatment could result in dramatic blood pressure control.
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& INTRODUCTION
International guidelines have defined resistant hyperten-
sion (RHT) as blood pressure that remains greater than the
goal despite the concurrent use of 3 different antihyperten-
sive agents (ideally, one of which is a diuretic) at the optimal
or best tolerated doses (1). Patients with RHT have a 3- to 6-
fold increased risk of fatal and nonfatal cardiovascular
events, compared with hypertensive patients whose blood
pressure is maintained within normal levels (2). Based on
recently published reports, the prevalence of RHT ranges
from 12% to 15% (3,4).
The recognition and treatment of secondary causes of
hypertension among patients with RHT could help to
control blood pressure and reduce cardiovascular risk (5).
Pedrosa et al. investigated 125 patients with RHT for known
causes of hypertension and they stated that obstructive
sleep apnea (OSA) was the most common condition
associated with resistant hypertension (64.0%), followed
by primary aldosteronism (5.6%), renal artery stenosis
(2.4%), renal parenchymal disease (1.6%), oral contraceptive
use (1.6%) and thyroid disorders (0.8%) (6). Upper airway
resistance syndrome (UARS) is another sleep-disordered
breathing syndrome that is classified as a subgroup of OSA.
It is characterized by snoring and repetitive occurrence of
respiratory effort-related arousals (RERAs) without oxygen
desaturation (7).
The association between OSA and RHT has been well
documented (8). Additionally, several reports have asserted
a positive correlation between the presence of chronic loud
snoring and stroke or hypertension (9,10). These reports,
however, have been unable to determine whether UARS is
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associated with RHT. Thus, in this study, we aimed to
determine whether UARS was associated with poorly
controlled hypertension.
& METHODS
Patient population
Between May 2009 and September 2011, patients who
were referred to our cardiology outpatient clinic with RHT
were enrolled in the study. RHT was defined according to
ACC-AHA RHT scientific statement criteria published in
2008 (1). All patients underwent 24-hour ambulatory blood
pressure monitoring to exclude white coat syndrome and to
monitor treatment efficacy. Patients with identifiable sec-
ondary causes (e.g. chronic kidney disease, renal artery
stenosis, Cushing syndrome, pheochromocytoma, coarcta-
tion of the aorta, hyperaldesteronism, acute thyroiditis,
metabolic syndrome, oral contraceptive use) were excluded
by means of biochemical and radiological tests.
Polysomnographic examination
Nocturnal polysomnographic monitoring included EEG
(14 channel), ECG (modified V2 lead), oronasal airflow
(using nasal cannulas), uncalibrated respiratory inductive
plethysmography, breathing sounds (by microphone), pulse
oximetry and body position. UARS was diagnosed accord-
ing to the American Sleep Disorders Association (ASDA)
criteria (nonapneic, nonhypopneic patients with snoring;
AHI ,5; and either RERA .10 or arousal index .10) (11).
OSA was defined as an AHI $5/h. The arousal index was
calculated according to the AASM (American Academy of
Sleep Medicine) score, which was calculated manually by
the investigators.
Statistics
The data were analyzed with the SPSS software, version
17.0 for Windows (SPSS Inc., Chicago, IL, USA). Normality
testing was performed using the Shapiro-Wilk test.
Continuous variables are expressed as means ¡ standard
deviations; categorical variables are expressed as numbers
and percentages. Continuous variables were compared
between UARS and non-UARS patients by the Mann-
Whitney U test and categorical variables were compared
via the chi-square test. Wilcoxon’s ranked pairs analyses
was applied to compare blood pressure levels before and
after treatment. Correlations between numerical variables
were calculated using Spearman’s correlation analyses. A p
value of 0.05 was utilized to indicate statistical significance.
& RESULTS
Forty patients (24 male, 16 female; mean age 38.3¡5.31
years old) with RHT were enrolled in the study. The
patients’ basal characteristics are summarized in Table 1.
The mean daytime systolic/diastolic blood pressure was
157¡3.93/96¡2.35 mmHg and themean night-time systolic/
diastolic blood pressure was 144¡4.92/88¡4.37 mm Hg.
Each patient was treated with at least 3 different antihyper-
tensive agents (mean 3.3¡0.464) (Table 2).
All patients underwent polysomnographic examinations;
22 patients (55%) were diagnosed with OSA and 14 patients
(35%) were diagnosed with UARS according to the ASDA
criteria. The UARS patients were younger and had a lower
body mass index (BMI) compared with the other patients,
while there were no differences in blood pressure levels or
the number of antihypertensive drugs (Table 3). Regarding
the main polysomnographic findings of the UARS patients,
the AHI was 4.23¡2.06 and the AI was 38.9¡14.2. The
mean Epworth score was 8.43¡2.73 for the patients with
UARS. The arousal index was correlated positively with
systolic blood pressure level (p= 0.034; rs = 0.746), while the
Epworth score and AHI were not correlated with the blood
pressure levels of UARS patients (p= 0.435, rs = 0.323 and
p= 0.819, rs = -0.097, respectively) (Table 4).
Among the 14 UARS patients, 2 patients had surgically
correctable upper airway pathology; positive airway pres-
sure (PAP) therapy was administered to the remaining 12
patients (7 intermittent PAP, 5 continuous PAP), but four
patients could not tolerate the treatment and were followed
medically.
The patients undergoing PAP therapy were followed for
six months. Following PAP therapy, the AIs of all the patients
decreased to less than 10. Blood pressure control was
achieved in all patients; five of them were followed under a
single-drug regimen, while the remaining three became drug
free. The mean blood pressure measurements before and
after treatment are shown in Table 5. No blood pressure
reductionwas observed in the patients who could not tolerate
PAP, and they were prescribed additional antihypertensives.
& DISCUSSION
The hypertension-related disease burden is substantial,
accounting for 62% of all strokes and 49% of all heart
diseases (12). Although most cases of hypertension can be
effectively treated with a net mortality and morbidity
benefit, hidden within this population is a cohort at the
extreme end of the cardiovascular risk spectrum: those
patients with RHT. This cohort consists of a group of
patients with secondary causes as well as those with true
drug resistance.
Obstructive sleep apnea is a well-known secondary cause
of RHT and its prevalence in drug-refractory hypertension
could be as high as 83% (8). The prevalence of OSA among
our relatively young and non-obese study population was
55%; hence, OSA should be borne in mind even in
clinically unsuspicious patients. Not only OSA but also
Table 1 - Basal characteristics of patients.
Age (years ¡ SD) 36.1¡5.66
Sex (male/female), n (%) 27 (67.5%)/13 (32.5%)
BMI (kg/m2¡SD) 31.8¡5.64
Smoking, n (%) 5 (12.5%)
BMI: body mass index.
Table 2 - Blood pressure measurements and number of
antihypertensive drugs.
Mean daytime systolic BP (mmHg¡SD) 157¡3.93
Mean daytime diastolic BP (mmHg¡SD) 96¡2.35
Mean night-time systolic BP (mmHg¡SD) 144¡4.92
Mean night-time diastolic BP (mmHg¡SD) 88¡4.37
Number of antihypertensive drugs (n¡SD) 3.40¡0.496
BP: blood pressure.
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other sleep-disordered breathing syndromes, including
simple snoring and UARS, have been consistently shown
to be associated with cardiovascular diseases (9-10).
UARS differs from OSA based on the absence of nocturnal
desaturation by definition and UARS is characterized by
nonapneic, nonhypopneic RERAs. These EEG arousals
result in ‘autonomic arousal,’ and sympathetic systemic
activity increases (7). Guilleminault et al. demonstrated
increases in heart rate and LF/HF index (sympathetic tone)
and a decrease in the HF component of HRV (parasympa-
thetic tone) in UARS patients (13).
The importance of vagal tone in blood pressure regulation
during sleep is known; normal subjects demonstrate a
decrease in mean arterial pressure of more than 10 mm Hg
during inspiratory strain, with a decrease in blood pressure
followed by an increase to greater than baseline on release
of the strain that is related to an increase in parasympathetic
stimulation. As UARS patients fail to increase in para-
sympathetic activity, repetitive increases in blood pressure
as a result of airway resistance episodes occur. UARS was
previously associated with borderline HT (14). Lofaso et al.
reported increased arterial systemic pressure following
nonapneic-nonhypopneic obstructive episodes, the magni-
tude of which varied with the level of arousal (15). Similarly,
our study revealed a positive correlation between AI and
blood pressure levels. Significantly higher systemic hyper-
tension was also demonstrated in 105 middle-aged, non-
apneic, sleep-fragmented (e.g. UARS) snorers (16).
Orthostatic hypotension has also been associated with
UARS, but studies linking RHT to UARS have been lacking
(17).
This study is the first report in the literature to suggest a
possible association between UARS and RHT. UARS was
present in 35% of our study population. Interestingly, 30%
of the UARS patients were asymptomatic; hence, the
diagnosis was clinically unsuspected. The reported symp-
toms were daytime sleepiness and snoring in most of the
cases, so clinicians should consistently ask about these
complains.
In addition to its high prevalence, the proper treatment of
UARS results in large blood pressure decreases and even
normalization of systemic arterial pressure. Patients who
could not tolerate PAP therapy failed to show improvement
in blood pressure levels. Interestingly, following PAP
treatment, the patients who became drug free were those
with lower AIs and this finding might further support the
role of UARS in RHT.
Upper airway collapsibility is the basis of UARS
pathophysiology. PAP treatment prevents airway obstruc-
tion due to collapsibility and results in decreased respira-
tory efforts, leading to repetitive arousals. However, it is a
double-edged sword because it can also trigger central
apnea due to iatrogenic hypocapnea.
The main limitation of our study was the relatively small
size of our series and the lack of a randomized design. We
aimed to determine whether UARS was associated with
RHT; however, this question requires a very large popula-
tion (e.g. an epidemiological study). Therefore, we consider
our results preliminary and we hope that this study will
pioneer further studies on this topic. Second, some details of
the histories and factors that might have influenced the
outcome might not have been completely documented.
Third, our study findings could potentially have been
Table 3 - Comparison of patients with upper airway resistance syndrome and non-upper airway resistance syndrome.
Upper airway resistance syndrome Non-upper airway resistance syndrome p-value
Age (years ¡ SD) 31.3¡5.31 38.7¡3.91 0.042
Sex (male/female), n (%) 9 (64.3%)/5 (35.7%) 18 (69.2%)/8 (30.8%) 0.812
BMI (kg/m2¡SD) 27.7¡6.03 33.9¡4.11 0.037
Mean daytime systolic BP (mm Hg¡SD) 156¡3.63 158¡4.03 0.110
Mean daytime diastolic BP (mm Hg¡SD) 95.8¡2.38 97.3¡2.22 0.048
Mean night-time systolic BP (mm Hg¡SD) 143¡6.45 145¡3.86 0.685
Mean night-time diastolic BP (mm Hg¡SD) 87.8¡4.27 88¡4.50 0.685
Number of antihypertensive drugs (n¡SD) 3.43¡0.514 3.38¡0.496 0.834
BP: blood pressure; *Mann-Whitney U test; **chi-square test.
Table 4 - Correlation between polysomnographic findings and blood pressure levels of upper airway resistance
syndrome patients.
Daytime systolic BP Daytime diastolic BP Night-time systolic BP Night-time diastolic BP
AHI (rs, p) -0.097, 0.819 -0.205, 0.627 0.370, 0.367 0.289, 0.487
AI (rs, p) 0.746, 0.034 0.055, 0.897 0.054, 0.899 0.146, 0.730
Epworth (rs, p) 0.323, 0.435 0.649, 0.081 -0.086, 0.840 0.072, 0.865
Table 5 - Efficacy of treatment in the upper airway resistance syndrome group.
Before treatment After treatment p-value*
Mean daytime systolic BP (mm Hg¡SD) 157¡4 129¡11 0.012
Mean daytime diastolic BP (mm Hg¡SD) 96.5¡3.07 82.1¡8.37 0.012
Mean night-time systolic BP (mm Hg¡SD) 139¡6 111¡10 0.012
Mean night-time diastolic BP (mm Hg¡SD) 87.7¡5.82 69.2¡4.49 0.012
BP: blood pressure; *Wilcoxon’s ranked pairs test.
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influenced by confounding factors. For example, cases
treated with CPAP who presented alleviation of high blood
pressure should be more intensively detailed in a larger
group of patients because a recent randomized trial in
patients with RHT and OSA found a positive but relatively
modest blood pressure reduction after CPAP (6). Finally, this
study was a single-institution study and although the patient
population andmanagement practices at our institution were
probably comparable to those in many other departments,
some caution should be taken before generalizing the
findings to other settings. Due to these restrictions, these
associations should be interpreted with caution.
In conclusion, although underappreciated, UARS is an
important cause of RHT and its proper treatment could
result in dramatic blood pressure control.
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